Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHASTA-5: plozasiran in adults with severe hypertriglyceridemia at high risk of acute pancreatitis
2024-518206-40-00Phase 3Authorised
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Nov 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia comparing Plozasiran with Placebo (2 arms). Primary endpoint: Time to first positively adjudicated acute pancreatitis event. Planned start Nov 2025; status: authorised.
02
Drugs
plozasiran
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on 2024-518206-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518206-40-00.